Coronary heart disease: the percentage of patients with coronary heart disease who are currently treated with a beta blocker (unless a contraindication or side-effects are recorded).

Brief Summary

TITLE

SOURCE(S)

British Medical Association (BMA). Quality and outcomes framework guidance for GMS contract 2008/09. London (UK): British Medical Association, National Health Service Confederation; 2008 Apr. 148 p.

Measure Domain

PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the Measure Validity page.

SECONDARY MEASURE DOMAIN

Does not apply to this measure

Brief Abstract

DESCRIPTION

This measure is used to assess the percentage of patients with coronary heart disease who are currently treated with a beta blocker (unless a contraindication or side-effects are recorded).

RATIONALE

Coronary heart disease (CHD) is the single commonest cause of premature death in the United Kingdom (UK). The research evidence relating to the management of CHD is well established and if implemented can reduce the risk of death from CHD and improve the quality of life for patients. This measure is one of ten Secondary Prevention of Coronary Heart Disease (CHD) measures. The "Secondary Prevention of Coronary Heart Disease (CHD)" indicator set focuses on the management of patients with established CHD consistent with clinical priorities in the four nations.

Long-term beta blockade remains an effective and well-tolerated treatment that reduces mortality and morbidity in patients with angina and patients after myocardial infarction.

Although the trial evidence relates mainly to patients who have had a myocardial infarction, experts have generally extrapolated this evidence to all patients with CHD. Because the evidence is not based on all patients with CHD, the target levels for this indicator have been set somewhat lower than for other process indicators.

Recent evidence against the use of beta blockers in hypertension should not be extrapolated to patients with CHD.

Refer to the Scottish Intercollegiate Guidelines Network (SIGN) guidelines, "Management of stable angina" (SIGN Publication No. 96, February 2007), and "Risk estimation and the prevention of cardiovascular disease" (SIGN Publication No. 97, February 2007) for further information.

PRIMARY CLINICAL COMPONENT

Coronary heart disease; beta blocker treatment

DENOMINATOR DESCRIPTION

Patients with coronary heart disease excluding patients with recorded contraindications or side-effects to beta blockers

NUMERATOR DESCRIPTION

Number of patients from the denominator who are currently treated with a beta blocker*

*Note: Beta blocker prescribed in the last six months

DATA SOURCE

Medical record
Registry data

Identifying Information

ORIGINAL TITLE

CHD 10. The percentage of patients with coronary heart disease who are currently treated with a beta blocker (unless a contraindication or side-effects are recorded).

MEASURE COLLECTION

Quality and Outcomes Framework Indicators

MEASURE SET NAME

Secondary Prevention of Coronary Heart Disease (CHD)

DEVELOPER

British Medical Association
National Health System (NHS) Confederation

FUNDING SOURCE(S)

The expert panel who developed the indicators are entirely funded by a grant from the English Department of Health.

COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE

The main indicator development group is based in the National Primary Care Research and Development Centre in the University of Manchester. They are: Professor Helen Lester, NPCRDC, MB, BCH, MD; Dr. Stephen Campbell, NPCRDC, PhD; Dr. Umesh Chauhan, NPCRDC, MB, BS, PhD.

Others involved in the development of individual indicators are: Professor Richard Hobbs, Dr. Richard McManus, Professor Jonathan Mant, Dr. Graham Martin, Professor Richard Baker, Dr. Keri Thomas, Professor Tony Kendrick, Professor Brendan Delaney, Professor Simon De Lusignan, Dr. Jonathan Graffy, Dr. Henry Smithson, Professor Sue Wilson, Professor Claire Goodman, Dr. Terry O'Neill, Dr. Philippa Matthews, Dr. Simon Griffin, Professor Eileen Kaner.

FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST

None for the main indicator development group.

ENDORSER

National Health Service (NHS)

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2004 Apr

REVISION DATE

2008 Apr

MEASURE STATUS

Please note: This measure has been updated. The National Quality Measures Clearinghouse is working to update this summary.

SOURCE(S)

British Medical Association (BMA). Quality and outcomes framework guidance for GMS contract 2008/09. London (UK): British Medical Association, National Health Service Confederation; 2008 Apr. 148 p.

MEASURE AVAILABILITY

The individual measure, "CHD 10. The Percentage of Patients with Coronary Heart Disease Who Are Currently Treated with a Beta Blocker (Unless a Contraindication or Side-effects Are Recorded)," is published in the "Quality and outcomes framework guidance." This document is available from the British Medical Association Web site.

NQMC STATUS

This NQMC summary was completed by ECRI on September 19, 2006. The information was verified by the measure developer on November 1, 2006. This NQMC summary was updated by ECRI Institute on January 7, 2009. The information was verified by the measure developer on February 9, 2009.

COPYRIGHT STATEMENT

No copyright restrictions apply.

Disclaimer

NQMC DISCLAIMER

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

Brief Summary

TITLE

SOURCE(S)

Measure Domain

PRIMARY MEASURE DOMAIN

SECONDARY MEASURE DOMAIN

Brief Abstract

DESCRIPTION

RATIONALE

PRIMARY CLINICAL COMPONENT

DENOMINATOR DESCRIPTION

NUMERATOR DESCRIPTION

DATA SOURCE

Identifying Information

ORIGINAL TITLE

MEASURE COLLECTION

MEASURE SET NAME

DEVELOPER

FUNDING SOURCE(S)

COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE

FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST

ENDORSER

ADAPTATION

RELEASE DATE

REVISION DATE

MEASURE STATUS

SOURCE(S)

MEASURE AVAILABILITY

NQMC STATUS

COPYRIGHT STATEMENT

Disclaimer

NQMC DISCLAIMER

Search

Summary

Browse

Compare